Used primarily in the treatment of overactive bladder (OAB) syndrome, this compound acts as a competitive muscarinic receptor antagonist. It helps reduce involuntary contractions of the bladder muscle by blocking the action of acetylcholine on muscarinic receptors in the urinary bladder. This results in decreased urgency, frequency, and episodes of urge incontinence. Due to its selectivity for bladder tissue over salivary glands, it tends to cause fewer dry mouth side effects compared to non-selective antimuscarinics. It is commonly formulated in extended-release tablets for once-daily dosing, improving patient compliance.